76 related articles for article (PubMed ID: 11503782)
1. Abciximab and percutaneous coronary intervention: new indications. Medium-term benefit.
Prescrire Int; 2000 Apr; 9(46):36-8. PubMed ID: 11503782
[TBL] [Abstract][Full Text] [Related]
2. Eptifibatide and tirofiban: new preparations. Limited benefit.
Prescrire Int; 2000 Oct; 9(49):135-8. PubMed ID: 11603412
[TBL] [Abstract][Full Text] [Related]
3. Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. c7E3 Fab Antiplatelet Therapy in Unstable Refractory Angina (CAPTURE) Study Investigators.
Hamm CW; Heeschen C; Goldmann B; Vahanian A; Adgey J; Miguel CM; Rutsch W; Berger J; Kootstra J; Simoons ML
N Engl J Med; 1999 May; 340(21):1623-9. PubMed ID: 10341274
[TBL] [Abstract][Full Text] [Related]
4. Evidence for prevention of death and myocardial infarction with platelet membrane glycoprotein IIb/IIIa receptor blockade by abciximab (c7E3 Fab) among patients with unstable angina undergoing percutaneous coronary revascularization. EPIC Investigators. Evaluation of 7E3 in Preventing Ischemic Complications.
Lincoff AM; Califf RM; Anderson KM; Weisman HF; Aguirre FV; Kleiman NS; Harrington RA; Topol EJ
J Am Coll Cardiol; 1997 Jul; 30(1):149-56. PubMed ID: 9207636
[TBL] [Abstract][Full Text] [Related]
5. Assessment of coronary angiograms prior to and after treatment with abciximab, and the outcome of angioplasty in refractory unstable angina patients. Angiographic results from the CAPTURE trial.
van den Brand M; Laarman GJ; Steg PG; De Scheerder I; Heyndrickx G; Beatt K; Kootstra J; Simoons ML
Eur Heart J; 1999 Nov; 20(21):1572-8. PubMed ID: 10529325
[TBL] [Abstract][Full Text] [Related]
6. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE Study.
Lancet; 1997 May; 349(9063):1429-35. PubMed ID: 9164316
[TBL] [Abstract][Full Text] [Related]
7. A risk-benefit assessment of abciximab in angioplasty.
Kleiman NS
Drug Saf; 1999 Jan; 20(1):43-57. PubMed ID: 9935276
[TBL] [Abstract][Full Text] [Related]
8. Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction) analysis.
Antman EM; Wiviott SD; Murphy SA; Voitk J; Hasin Y; Widimsky P; Chandna H; Macias W; McCabe CH; Braunwald E
J Am Coll Cardiol; 2008 May; 51(21):2028-33. PubMed ID: 18498956
[TBL] [Abstract][Full Text] [Related]
9. [Use of abciximab during coronary angioplasty].
Philippe F; Montalescot G; Drobinski G; Thomas D
Arch Mal Coeur Vaiss; 1997 Dec; 90(12):1645-50. PubMed ID: 9587446
[TBL] [Abstract][Full Text] [Related]
10. On the use of abciximab in percutaneous coronary intervention.
Iversen AZ
Dan Med Bull; 2011 Aug; 58(8):B4312. PubMed ID: 21827726
[No Abstract] [Full Text] [Related]
11. Reduction of recurrent ischemia with abciximab during continuous ECG-ischemia monitoring in patients with unstable angina refractory to standard treatment (CAPTURE).
Klootwijk P; Meij S; Melkert R; Lenderink T; Simoons ML
Circulation; 1998 Oct; 98(14):1358-64. PubMed ID: 9760288
[TBL] [Abstract][Full Text] [Related]
12. Abciximab therapy in percutaneous intervention: economic issues in the United States.
Goklaney AK; Murphy JD; Hillegass WB
Eur Heart J; 1998 Apr; 19 Suppl D():D52-8. PubMed ID: 9597522
[TBL] [Abstract][Full Text] [Related]
13. Abciximab. An updated review of its use in ischaemic heart disease.
Foster RH; Wiseman LR
Drugs; 1998 Oct; 56(4):629-65. PubMed ID: 9806109
[TBL] [Abstract][Full Text] [Related]
14. Minimal myocardial damage during coronary intervention is associated with impaired outcome.
Simoons ML; van den Brand M; Lincoff M; Harrington R; van der Wieken R; Vahanian A; Rutsch W; Kootstra J; Boersma E; Califf RM; Topol E
Eur Heart J; 1999 Aug; 20(15):1112-9. PubMed ID: 10413641
[TBL] [Abstract][Full Text] [Related]
15. An overview of the results of the EPIC trial.
Califf RM; Lincoff AM; Tcheng JE; Topol EJ
Eur Heart J; 1995 Nov; 16 Suppl L():43-9. PubMed ID: 8869018
[TBL] [Abstract][Full Text] [Related]
16. Multi-year follow-up of abciximab therapy in three randomized, placebo-controlled trials of percutaneous coronary revascularization.
Topol EJ; Lincoff AM; Kereiakes DJ; Kleiman NS; Cohen EA; Ferguson JJ; Tcheng JE; Sapp S; Califf RM
Am J Med; 2002 Jul; 113(1):1-6. PubMed ID: 12106616
[TBL] [Abstract][Full Text] [Related]
17. Percutaneous revascularization for unstable angina in the elderly.
Hirsch H; Lazar J; Marzo KP; Steingart RM
Coron Artery Dis; 2000 Jun; 11(4):315-22. PubMed ID: 10860174
[No Abstract] [Full Text] [Related]
18. Predictive value of C-reactive protein and troponin T in patients with unstable angina: a comparative analysis. CAPTURE Investigators. Chimeric c7E3 AntiPlatelet Therapy in Unstable angina REfractory to standard treatment trial.
Heeschen C; Hamm CW; Bruemmer J; Simoons ML
J Am Coll Cardiol; 2000 May; 35(6):1535-42. PubMed ID: 10807457
[TBL] [Abstract][Full Text] [Related]
19. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. An industry perspective on health economics studies.
Anderson KM; Bala MV; Weisman HF
Am Heart J; 1999 May; 137(5):S129-32. PubMed ID: 10220615
[No Abstract] [Full Text] [Related]
20. Abciximab therapy in percutaneous intervention: economic issues in the United States.
Goklaney AK; Murphy JD; Hillegass WB
Am Heart J; 1998 Apr; 135(4):S90-7. PubMed ID: 9539499
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
